Ladenburg upgraded Forte Biosciences to Buy from Neutral with a $2.75 price target. The company’s FB-102 is an anti-CD-122 antibody in development for the treatment of graft versus host disease, the analyst tells investors in a research note. The firm says that if approved, FB-102 would be the first CD122 antibody in the treatment of GVHD. Despite three approved treatments there remains a significant unmet need in GVHD, and FB-102’s data has been impressive, says Ladenburg.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBRX:
